Omvoh 300 mg concentrate for solution for infusion clinical trials

I6T-MC-AMBA - A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moderately to Severely Active Ulcerative Colitis

This study is looking at a new medicine, Mirikizumab (also called Omvoh), for children and teenagers aged 2 to under 18 who have moderate to severe ulcerative colitis. We want to see how well it works and if it's safe to help them feel better.